{"ticker": {"uuid": "3c4bc3fc-9a56-49a2-b297-d5d651099723", "symbol": "ARQT", "name": "Arcutis Biotherapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Arcutis to report Q2 2026 financial results on August 5", "summary": "Arcutis Biotherapeutics will announce its second quarter 2026 financial results and provide a business update on August 5, 2026, after U.S. markets close. A conference call and webcast are scheduled for 4:30 p.m. ET on the same day, accessible via the company's investor website. ", "url": "https://scanx.trade/stock-market-news/companies/arcutis-to-report-q2-2026-financial-results-on-august-5/45697049", "source_name": "scanx.trade", "published_at": "2026-07-15T21:47:09", "published_display": "15 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026", "summary": "Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET on t", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/arcutis-to-report-second-quarter-2026-financial-results-and-host-conference-call-on-august-5-2026/2385428/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares", "summary": "Arcutis Biotherapeutics shareholder Howard Welgus plans to sell 4730 common shares through Merrill Lynch on NASDAQ around July 15, 2026, with an estimated market value of $127,284.3. These shares originate from restricted stock vesting and stock option exercises. The filing also ", "url": "https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-0626da98e6a5.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis schedules Aug. 5 webcast for its business update", "summary": "Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, accessible via the ", "url": "https://www.stocktitan.net/news/ARQT/arcutis-to-report-second-quarter-2026-financial-results-and-host-i4h6td3vd15v.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Arcutis application for infant eczema treatment By Investing.com", "summary": "The FDA has accepted Arcutis Biotherapeutics Inc.'s supplemental New Drug Application for ZORYVE cream 0.05% to treat atopic dermatitis in infants aged 3 to 24 months, setting a target action date of February 23, 2027. This application is supported by positive Phase 2 and Phase 1", "url": "https://ng.investing.com/news/stock-market-news/fda-accepts-arcutis-application-for-infant-eczema-treatment-93CH-2590941", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T14:41:52", "published_display": "14 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Understanding Momentum Shifts in (ARQT)", "summary": "The article highlights strong sentiment for Arcutis Biotherapeutics Inc. (ARQT) across all time horizons, supporting an overweight bias. It identifies a mid-channel oscillation pattern and an exceptional 67.9:1 risk-reward setup targeting a 20.2% gain against 0.3% risk. The analy", "url": "https://news.stocktradersdaily.com/news_release/22/Understanding_Momentum_Shifts_in_ARQT_071126052201_1783804921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T17:22:00", "published_display": "11 Jul 2026 17:22", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies", "summary": "Jefferies has maintained a \"Buy\" rating on Arcutis Biotherapeutics (ARQT) with a price target of $35.00. The company reported significantly improved quarterly revenue and a reduced GAAP net loss compared to the previous year, although corporate insider sentiment is currently nega", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARQT/pressreleases/3225315/arcutis-biotherapeutics-arqt-receives-a-buy-from-jefferies/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T13:11:05", "published_display": "11 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (ARQT) Following FDA Acceptance For ZORYVE Is The Upside Still There", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T02:21:36+00:00", "published_display": "10 Jul 2026 02:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTGFDakUtMkg4bWZSZ2VhYWhLX2lqWTlYeThwTGN2akViaUktWVVnUk9PaFdPX3JaX2o2U1Fjcy1uc2tlYklYcVlvcC0wODA1NG1KT1dCR0gxdlpVNW9FZEd4QmpmUktub3ZPQWc1UVV1NmNiQU5tNTlCaUpxWjVCRFBOY2hVdzNuY2ZFcVhIQ1BRQkxYOHVSVE1vZUdVUTFTWkNoVTJsWTRwb1FaV3Z5d2hJTnpGLURfVjV1cA?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-09T17:37:00+00:00", "published_display": "09 Jul 2026 17:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Arcutis Biotherapeutics, Inc. \u2013 NASDAQ:ARQT", "summary": "This article provides financial data for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) on TradingView, specifically focusing on its forward price-to-earnings ratio. It presents a snapshot of the company's financial performance, indicating market status as closed with no trades. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ARQT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T01:47:09", "published_display": "09 Jul 2026 01:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35", "summary": "Mizuho Securities has reiterated its \"Buy\" rating for Arcutis Biotherapeutics (ARQT.US) and maintained its target price at $35. This indicates a continued positive outlook from the firm regarding the biotechnology company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/72663274/mizuho-securities-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-09T01:09:02", "published_display": "09 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy?", "summary": "Arcutis Biotherapeutics received FDA acceptance for a supplemental New Drug Application for ZORYVE cream 0.05% to treat atopic dermatitis in infants, expanding its focus within non-steroidal dermatology treatments. This move deepens the company's reliance on its single-drug strat", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/could-arcutis-arqt-infant-label-bid-clarify-the-limits-of-it", "source_name": "Simply Wall Street", "published_at": "2026-07-08T21:09:30", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD", "summary": "The US FDA has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) to treat mild-to-moderate atopic dermatitis in infants aged three to 24 months, setting a PDUFA target date of February 23, 2027. The sNDA is supported b", "url": "https://thedermdigest.com/us-fda-sets-pdufa-for-roflumilast-cream-0-05-in-infants-with-ad/", "source_name": "The Dermatology Digest", "published_at": "2026-07-08T20:09:30", "published_display": "08 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-says-fda-accepted-125906712.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:59:06+00:00", "published_display": "08 Jul 2026 12:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants", "summary": "Arcutis has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.005% for the treatment of mild-to-moderate atopic dermatitis in infants aged 3 months to less than 6 years. The FDA has set a Prescription Drug User Fee A", "url": "https://www.moomoo.com/news/post/72652160/arcutis-fda-to-review-zoryve-for-atopic-dermatitis-in-infants?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T13:09:31", "published_display": "08 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Arcutis application for infant eczema treatment", "summary": "The FDA has accepted Arcutis Biotherapeutics Inc.'s application for ZORYVE cream 0.05% to treat atopic dermatitis in infants aged 3 to 24 months, setting a target action date of February 23, 2027. This follows positive results from a Phase 2 study and comes as Arcutis shares have", "url": "https://www.investing.com/news/company-news/fda-accepts-arcutis-application-for-infant-eczema-treatment-93CH-4781489", "source_name": "Investing.com", "published_at": "2026-07-08T13:09:30", "published_display": "08 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months", "summary": "The FDA has accepted Arcutis' Supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants as young as three months old. This sNDA is supported by positive results from the Phase 3 INTEGUMENT-PED study. If ap", "url": "https://www.moomoo.com/news/post/72651104/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast", "source_name": "Moomoo", "published_at": "2026-07-08T12:10:58", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Supplemental New Drug Application for Arcutis\u2019 ZORYVE\u00ae (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months", "summary": "Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for ZORYVE\u00ae (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA has set a target action date of February 23, 2027. Th", "url": "https://www.manilatimes.net/2026/07/08/tmt-newswire/globenewswire/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-005-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months/2380726/amp", "source_name": "The Manila Times", "published_at": "2026-07-08T12:09:31", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis wins FDA review for ZORYVE in infants as young as 3 months", "summary": "Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA has set a PDUFA target action date of February 23, 202", "url": "https://www.stocktitan.net/news/ARQT/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-dzxv8c9m3k4i.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:09:30", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Arcutis Biotherapeutics, Inc. \u2013 NASDAQ:ARQT", "summary": "This article provides the \"Price to sales forward\" financial metric for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It appears to be a financial data snippet from TradingView, without further elaborating on the value or implications of this metric. The content focuses on the co", "url": "https://www.tradingview.com/symbols/NASDAQ-ARQT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T18:40:35", "published_display": "05 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Comparative Analysis of Arcutis and Vertex Biotherapeutics", "summary": "This article provides a comparative analysis of Arcutis Biotherapeutics and Vertex Pharmaceuticals based on their FY 2025 financial performance, market position, and future outlook. Arcutis showed significant revenue growth but faces stiff competition and patent litigation for it", "url": "https://intellectia.ai/news/stock/comparative-analysis-of-arcutis-and-vertex-biotherapeutics", "source_name": "Intellectia AI", "published_at": "2026-07-03T14:41:28", "published_display": "03 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/2e75dc09-2807-3507-941d-d552f859c2c8/arcutis-vs.-vertex%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-07-03T12:57:20+00:00", "published_display": "03 Jul 2026 12:57", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Arcutis Biotherapeutics, Inc. announced the grant of 61,000 restricted stock units (RSUs) to 9 newly hired employees. These grants were made under the company's 2022 Inducement Plan, with a grant date of July 1, 2026, as a material inducement for their employment. The RSUs will v", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377798/amp", "source_name": "The Manila Times", "published_at": "2026-07-02T19:40:30", "published_display": "02 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis lures 9 new hires with 61,000 stock awards", "summary": "Arcutis Biotherapeutics (Nasdaq: ARQT) has granted an aggregate of 61,000 restricted stock units (RSUs) to nine new employees under its 2022 Inducement Plan. These awards, approved by the Board\u2019s Compensation Committee, were granted on July 1, 2026, and will vest 25% annually ove", "url": "https://www.stocktitan.net/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-vjhqlzgvqj91.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:12", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36", "summary": "Needham has reiterated its Buy rating for Arcutis Biotherapeutics (ARQT.US) and maintained its price target of $36. This indicates continued confidence in the company's stock performance and future prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/72276591/needham-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-01T21:39:13", "published_display": "01 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis launches virtual dermatology platform for skin conditions", "summary": "Arcutis Biotherapeutics has launched a virtual health platform to connect patients with board-certified dermatologists for chronic inflammatory skin conditions like eczema and psoriasis. This initiative aims to expand access to care, complementing traditional in-office visits, an", "url": "https://www.investing.com/news/company-news/arcutis-launches-virtual-dermatology-platform-for-skin-conditions-93CH-4768064", "source_name": "Investing.com", "published_at": "2026-07-01T09:11:09", "published_display": "01 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should ZORYVE\u2019s New Pediatric Label and Virtual Platform Expansion Require Action From Arcutis (ARQT) Investors?", "summary": "Arcutis Biotherapeutics received FDA approval to extend ZORYVE cream treatment to children aged 2\u20135 and launched a virtual health platform to connect patients with dermatologists. This expansion supports Arcutis's revenue goals and broadens access to care, but investors should we", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/should-zoryves-new-pediatric-label-and-virtual-platform-expa/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T08:40:50", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast", "summary": "Arcutis Biotherapeutics is introducing a new virtual health platform to enhance access to its roflumilast (Zoryve) treatments for chronic inflammatory skin diseases like atopic dermatitis, seborrheic dermatitis, and plaque psoriasis. This platform connects individuals with indepe", "url": "https://thedermdigest.com/arcutis-launches-virtual-dermatology-platform-to-boost-access-to-roflumilast/", "source_name": "The Dermatology Digest", "published_at": "2026-06-30T16:40:11", "published_display": "30 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ARQT) Movement", "summary": "The article provides a real-time analysis of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), highlighting a near-term neutral sentiment amid stronger mid and long-term outlooks. It details institutional trading strategies, including long and short setups with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/24/Avoiding_Lag:_Real-Time_Signals_in_ARQT_Movement_063026041402_1782850442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:40:11", "published_display": "30 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis launches virtual dermatology platform for skin conditions By Investing.com", "summary": "Arcutis Biotherapeutics has launched a virtual health platform connecting patients with board-certified dermatologists for chronic inflammatory skin diseases like eczema and psoriasis. The platform aims to address barriers to in-person care and expand access to diseases for the c", "url": "https://ca.investing.com/news/stock-market-news/arcutis-launches-virtual-dermatology-platform-for-skin-conditions-93CH-4714064", "source_name": "Investing.com Canada", "published_at": "2026-06-30T13:40:11", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE\u00ae (roflumilast) Indications", "summary": "Arcutis Biotherapeutics has launched a new virtual health platform to improve access to care for individuals with chronic inflammatory skin diseases, including those eligible for ZORYVE. The platform connects patients with independent, board-certified dermatologists through a str", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-individuals-living-with-chronic-inflammatory-skin-diseases-including-approved-zoryve-roflumilast-indications/2375921/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T13:40:11", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-wins-fda-approval-083519488.html", "source_name": "MT Newswires", "published_at": "2026-06-30T08:35:19+00:00", "published_display": "30 Jun 2026 08:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis\u2019 new virtual dermatology platform targets care gaps for 45M Americans", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOUUd6dWM2SHI0cHZNMFV4TDRqNWZCWm96RWpMeENBYkxRTU9MQU82NlJCTjBKdXRpd0NFc1l5NHhnWndrcnpIQU5zN1h6U053c2cxaDliMVB4QXVuV2tCaWdhd0l4bm9KTGlsSXFHV3hDUTBkNzBXMG9DVTZkWjNLTTRSUzBSTmxMY0hOanlmN0R2UHVoMW9Cb25ta3phclRIaGR3eWFUbzVISktvVFljQ2RCMzgwcGVmOWcxeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2", "summary": "Arcutis Biotherapeutics announced FDA approval for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as two, marking it as the first once-daily, non-steroidal topical treatment for this age group. This approval addresses a significant treatment gap, offering a safe", "url": "https://www.quiverquant.com/news/Arcutis+Biotherapeutics+Announces+FDA+Approval+of+Expanded+ZORYVE+Cream+0.3%25+Indication+for+Children+With+Plaque+Psoriasis+Down+to+Age+2", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T22:10:05", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQYjcySGlSREM4OUd5ZmU0WU5BWnRQanF6UmN4NUJBaVg3eUJrTWhBcG5lMHgxNUx0ZGZpRjlpRXpVZTBvSjdpeHlBRDdKYk4xMW9mQ0hvQkRRc1BzZ05EdUt5ZHNNX0R0TndULWIwUFhrd3g1c2FrSlF2TGd4RmYySGZyV3lBZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T23:38:28+00:00", "published_display": "25 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNQVEwQTFqR1FQMlJSbEZaMzRxZHNUVldzQlFSRmxPOTBNQU41M0pUd1N0akZmUExocDc3ckN4aTdrdlU2ajNDT3ZQYS1TX2N1blUtQzRTUlk3LUNFMTZuNFdEZTZHMmtFdnZCbDFRV3pUc0NjRDFySktlRTNJVlVpa3RGV3RrMk05THJkYWM2UWwyRlZKcUpTeUxxMk10TG1EWUtLd21CbEp1b0c4UXFMS21CdkJCXzQ1QVNjQlJlcm0xN2FrVEZBTjNpNA?oc=5", "source_name": "ChartMill", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS1ZMS3JIX3g3eURvVy1oVmYxX0k2N0o0dmNWbGhZMTRKUU1LOEpUd3ptUE9TT2RtTi1NV1VBLXdyWkxEZXdPRHBSYUJZTGtzMlUtVGVSNmZmZVFWelRFRnZXeGhBMWh6dlg4c2RsMjVYNkU0eW5TWHNaNkg2WW4wRURBb05PcFV5Y0w5eFVYYlowN044eDM4MzhzOTQ3aWVfbVFqSElOOWtJNG1tMWFFN1VEb3lIdGVzZ0R5T0FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Howard Welgus sells 21,240 ARQT shares (NASDAQ: ARQT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZjE3OXZjSk1JOHJCY3RIeHZiYUlZcUR6YVlvdmk4b2JqajJHeVdnckxaOEc3TEw4TUFCeWNPN0hvcy1HajJNOHlVTkU3WWZUVzJKdGt4c0ttV2ZDaVZaSXZpU2pxVTlWR3V2SklNUTVBdUtBTzBXVVpNYy1RVV9KYVBxSHpueDlwOU1NdnFpQ2RMQ0ctTFNwVEpYUDhWMmVKS1RNU2VJaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis (ARQT) director Sue-Jean Lin executes planned share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOdmRTU0VVclVuaVFsVGpHWUUwdUxYcmVrS3o3eDAzd2RsLWJRWG0tOFVCUzhoNU1MOVY5LXI1dlJEX2dPQzg3YkxzOVplRnp2YjBQbElYdlVrdjlSVnIyN0ZTczNUODJ1RWFBYmRXY095Yk5RcXFONThoeDV5Qm5xM2R2RlRpRnM2Y3QtakRCQ0haakRYVXBWRklyUlFkaWItOHFSWHE5N2Vyb1AtQ0lCRlBzYmY2SWlERldEY3Vn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Genital Psoriasis Clinical Guidance Publication", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcutis Biotherapeutics ARQT Tighter Trailing Losses Test Bullish Profitability Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNNjdMc2JtLWpfVXdqQzF0ZkllRkZNaDJUczFVYlhLT1RVcXpDZDNmYjZFd0JFRUpyTFJPbktpQTlyVHdJOXpWLXFtUG8tMjY2ZkR1R0xLYjBMLWhqYjBfdFBsTDZVVHVQVl9mQ1BmcUpGRUlFSXhFanctb014OEZrRjlCVkZsY0xoOTZNbEpndy1LNkVvaW1qSl9DZ0RaTWtxVUhmVklwaVBvMy1WWEtPSmlvNnA3Y1JVNjl0dkN0M01oWjRHMXNHOUE3VFNSMkpiUmkyV3VSNG83TFpQUzF4djR0MWtWM0Z3dnoyN2dR0gHzAUFVX3lxTFB5aENocEx1MEJCaVk4eVNoMjV5UDVYM0FtRVAtYmZaeGkxM0RTb2NKdk9DSDRXWHBtbHhVNk1UZjFWcEVHSm5zNVQyT3RWcjF0b1I2RGNoZXRWUDRJZjhXYnBQZ3ZOQ2JsU2d1WDZ3WUJ0ZFpHRXpkZ2Q4aldKQU80M3hTLTBkRTVYbTdEeV9zX0NLTEE2V2JGRzJOaEhGeFhONjcyRFNvdHVneGhBb3JQOENOc184aXpmRDRRbm9UeEJkelZuUkQ0eGh6TFRXa3RQdGFBMjdHYWFIckRZSGdEeERZb2ktamo2YWJOWV9TblRWNA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOdV9DcTFEZmk2YlVSOGwwUDM5d0NERlBoeFJZNXBCT29xQjlTLWRCbTczNjg3alp4RzdkX3RHVWx4UXdzaTRwN3RtVUdNRHFnTUk0LUJCMHl3RVZDbU5rUXVkTG9ZUHd0MXdCdS1JbDUtMkd6LVFDUWM3NmU3Q2hFRHh0NGhONjVOR1hwYURCRC12UDFw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNNmhoZHhENlNpdlE2S0lTeVFoNXYzVzQ4a1k5RGhoUmFxNUdJMTFnUmxPVGVMakw2azNEWXJsOHozcC10SjY3bVNJb3pFeDc0SWFJb1U4eFAyNE5sbjBFeG9RS3ItUmhlRHd3SXY1bnRzUUc4SHNhTHNld3ZhYnF4eVpzbkI0MzR3NWNJS3QxRE96S0dTQkx3MXZDMGMzTTBuVUZhRTA0cUVtQ3FUZ0E?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQekVpbFlvWnhxV2pyX25lRmNseDZXZXNMVHNEUUFYcmlfM1duclJVa0Q4UXhMa0tzand2MlR0VUNkZGljbE1QcUFPUXFud1RJNEdHWW5EMGVvQWlEa0VybnNVeDVSaTY1LXNqTElMRnhkNEw5cmxiRmotSDZOS2xKV3pkQWd2akhwNUp5M3kyTVFQYTd3dW9aRlVxbkUwVDVTbHZfclBVRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMW5lS013YjJPVV92bU1nNkFhQVNQMXUyOWVKSkhiLWNuWkplTzVyT0FtcXNhRklJZFpaZG5BSTBJR3BFNjN0U3BLSXdSWXFEQ005ZzZtUUVlRnhBdU1GWFBOOG5STTdQc1ZqWVhMRlQyWlFwNmtxT1lOa1p5U0MwZXcySi0tS2hpWFRFWVlBT1hTR0tOY3gtc3VveEhsazRMdTBPeC1fSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOYUZPQzBnS2RwejRhRFl2a3R3dXNSdkNFd3FKWjF5b1R4bzhENE1ESTNaVkRWWWZFcktKSDVGcnppcV9WTFpsQ1k2NUFvMnlRMnBLdHVxZWVUOWFvVVpDSkRLT2RENVFqejd6RHAwZTFqMnpMazU5bHVJdlE1WTF6bTNiWE9DVTJLS2JlREpVSEgxdzVfczhEUnRmdGZFWVFuT3dSZ3ZFYw?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQV0ZGOTlySG93TzhzQVhPNUxXNFgzRnEwVmZQaTV4Q1JWcnNPME8ycEdpNmpIQkIxdmRCdUpNd1g2ZXZTQ2EzUHBfTkpueGZ0T2M1ZHEtaUJic1p3S3Vnc1R4a01pckMxZVR4MUNaZEw3Y2ZUTWxvRy1UNTBlbnlQeUJlczlBdFJSRENncHVOb1c5Ni1iZ0prV3JhUDE5bzVoQWpYNGJGZlNZekIxbEFKMXZR?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOaGI4bDJYaDVJd2ttX1hubWdQbUNYMFZ6Rk9EeTBIdG83NS1aZXluaTVOVlFxRVE3cmVlTUdHMGhXVGxsS25iaU92VHlZczJyYkdmUG9rSUpLeGFVb253NXhDdWtMTUMxZG5qbXFucEFaX2lNOS1aYVAwaGV1M0xjb1dFRmZEOEg0czRMSG1sTnNSYzdpY25OU05Cck9wcE5RZk12LVZvU05uMUFJWUJndjlRbjIxTENUYzdzT0J1S25SSUVOYlFhQXJzWU5WWXphZ3Bldm02bTlpZEU?oc=5", "source_name": "ChartMill", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNRGJmU3k2cVIxSURPemsyQ053NWM3SHhzUHZLZTlvSU9uQnR5UFdOU0k0RVREMEtRNEVNRFNrQmYwanhvT2FfUnp1OW04SEp0SXZrZUdEZWJNRk8zcVZSMDNWVDN5TnNDSlNHWEFobUdPMlBjUWVVS2s5UDJfLVMzcVVBUFROZXFiZnRqS3E4Z2NDdzlxRXJySXpPclRCNzl5TGhoMldJSzdCSEpMMmc?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUTJOQVdhc19UZEh0MzFWN0RmclZ2ZWNWbXladnZvcmJFMkU3TWQ1cURLUHVCWlJlNzBfQ1RkS0JUSl9hYTU2Mnd4bXF5QjdVTEYwZ0ZxNGhpNkI1ejdGWW5ETUJ5VkU2dlFLa1d3a2pKMDF6TVNfMjFVQ1djNzQzb3NVTEZublBMeWF2SzNCVWVsZ1MzSDFHZjRxb2k?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNQ3dodXJ4TDRycGRRTmJqcExnS1NVcDBJQXJBVDI5d21rc1owMFNUMDFTVnpyZ05LUThhdW93XzB5T1REQVRRekhFV2Nqb1Y4UjB0OERHMEQtMTFBeGUyekU4c29VbWRoNDNvN21hTFZTT0RXbHhqelZFckRoVFRXSXFR?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) files shelf for multiple securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUFJzeDBnOElmclU3Vzl0emwtdWIySEZfd2xkaVJwMENFaHpZZXlBTkx2UEROcklHVFJ0c3hKdE84akxVMEJlUkUxbElJWnhUWUNyYVlkVGpCRHBuZ2xZOHRLdDBmZjdaN2h6TnNEVXRNUEI0aUhCSzl5UUZKekd0dXFLajNleVdRQzB6V2pEcnFVdGRJS3p4R1NhNmVkSVJkOVJjM09ySjVMc00?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Arcutis to report Q2 2026 financial results on August 5", "summary": "Arcutis Biotherapeutics will announce its second quarter 2026 financial results and provide a business update on August 5, 2026, after U.S. markets close. A conference call and webcast are scheduled for 4:30 p.m. ET on the same day, accessible via the company's investor website. ", "url": "https://scanx.trade/stock-market-news/companies/arcutis-to-report-q2-2026-financial-results-on-august-5/45697049", "source_name": "scanx.trade", "published_at": "2026-07-15T21:47:09", "published_display": "15 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026", "summary": "Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET on t", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/arcutis-to-report-second-quarter-2026-financial-results-and-host-conference-call-on-august-5-2026/2385428/amp", "source_name": "The Manila Times", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares", "summary": "Arcutis Biotherapeutics shareholder Howard Welgus plans to sell 4730 common shares through Merrill Lynch on NASDAQ around July 15, 2026, with an estimated market value of $127,284.3. These shares originate from restricted stock vesting and stock option exercises. The filing also ", "url": "https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-0626da98e6a5.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis schedules Aug. 5 webcast for its business update", "summary": "Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 5, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, accessible via the ", "url": "https://www.stocktitan.net/news/ARQT/arcutis-to-report-second-quarter-2026-financial-results-and-host-i4h6td3vd15v.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:47:09", "published_display": "15 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Arcutis application for infant eczema treatment By Investing.com", "summary": "The FDA has accepted Arcutis Biotherapeutics Inc.'s supplemental New Drug Application for ZORYVE cream 0.05% to treat atopic dermatitis in infants aged 3 to 24 months, setting a target action date of February 23, 2027. This application is supported by positive Phase 2 and Phase 1", "url": "https://ng.investing.com/news/stock-market-news/fda-accepts-arcutis-application-for-infant-eczema-treatment-93CH-2590941", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T14:41:52", "published_display": "14 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (ARQT)", "summary": "The article highlights strong sentiment for Arcutis Biotherapeutics Inc. (ARQT) across all time horizons, supporting an overweight bias. It identifies a mid-channel oscillation pattern and an exceptional 67.9:1 risk-reward setup targeting a 20.2% gain against 0.3% risk. The analy", "url": "https://news.stocktradersdaily.com/news_release/22/Understanding_Momentum_Shifts_in_ARQT_071126052201_1783804921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T17:22:00", "published_display": "11 Jul 2026 17:22", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies", "summary": "Jefferies has maintained a \"Buy\" rating on Arcutis Biotherapeutics (ARQT) with a price target of $35.00. The company reported significantly improved quarterly revenue and a reduced GAAP net loss compared to the previous year, although corporate insider sentiment is currently nega", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARQT/pressreleases/3225315/arcutis-biotherapeutics-arqt-receives-a-buy-from-jefferies/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T13:11:05", "published_display": "11 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (ARQT) Following FDA Acceptance For ZORYVE Is The Upside Still There", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOanBEcEZCTVZUREU3TlB2NXU3Uzcxd1g1RVpYMk51bFVYTFpzeXZ6UUl3T1RCTGkxUlVWamFVcHVYYzB4c1QyR3JWb1lPVUZmaXI3UjQ2RjZGQjBxM05Xb2lsRHBHZUJXVlJtbE1ZQlJuT0JwTXlpZk9vX2c1VTdiMEZTTUlXSmUyY2dnLVh1VzlLWUx0QlRmZ2VVUE00cDV4aUdWUnhCVWc4WERIZ1ZXUjVMZVRjSEhfM3VGcXBObEJablVkWFFCZWhGQ042QXA2b0NIdTVNWm0zMGgwT3FsUnVsMVZaWGcyUWVXXzBn0gHzAUFVX3lxTE03VEkwWkhPZDVCN1piY2w4WFg3UjA2bU5hbU5FM0VaMEtuZjlaUnI3VUJ1Vlp2N3BzeTlGZEhaLVloQVZyVnNwVTF1WG9qQjVfdFdUQlBKMFRNbmJybmk5eVdVSWFTVm9BYW5TeEtTcXVzQmtFM0wyZk5kMV9qTWtqSURUb3p2SFY0ZXk4NS1WemlhNmE4VUVWVmpSRU5VNVNTaUh5cU5oN0xscFhDN3hyejB5eFRiOGJCMUJUM3dxM1pVSG0wNXFLNFhYR1hlN05OVkR6NEZTNjcxVDcyWUk4cVppWnRMZUJMQUpxY1VrQmh4SQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T02:21:36+00:00", "published_display": "10 Jul 2026 02:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTGFDakUtMkg4bWZSZ2VhYWhLX2lqWTlYeThwTGN2akViaUktWVVnUk9PaFdPX3JaX2o2U1Fjcy1uc2tlYklYcVlvcC0wODA1NG1KT1dCR0gxdlpVNW9FZEd4QmpmUktub3ZPQWc1UVV1NmNiQU5tNTlCaUpxWjVCRFBOY2hVdzNuY2ZFcVhIQ1BRQkxYOHVSVE1vZUdVUTFTWkNoVTJsWTRwb1FaV3Z5d2hJTnpGLURfVjV1cA?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-09T17:37:00+00:00", "published_display": "09 Jul 2026 17:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Arcutis Biotherapeutics, Inc. \u2013 NASDAQ:ARQT", "summary": "This article provides financial data for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) on TradingView, specifically focusing on its forward price-to-earnings ratio. It presents a snapshot of the company's financial performance, indicating market status as closed with no trades. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ARQT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T01:47:09", "published_display": "09 Jul 2026 01:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35", "summary": "Mizuho Securities has reiterated its \"Buy\" rating for Arcutis Biotherapeutics (ARQT.US) and maintained its target price at $35. This indicates a continued positive outlook from the firm regarding the biotechnology company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/72663274/mizuho-securities-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-09T01:09:02", "published_display": "09 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy?", "summary": "Arcutis Biotherapeutics received FDA acceptance for a supplemental New Drug Application for ZORYVE cream 0.05% to treat atopic dermatitis in infants, expanding its focus within non-steroidal dermatology treatments. This move deepens the company's reliance on its single-drug strat", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/could-arcutis-arqt-infant-label-bid-clarify-the-limits-of-it", "source_name": "Simply Wall Street", "published_at": "2026-07-08T21:09:30", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD", "summary": "The US FDA has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) to treat mild-to-moderate atopic dermatitis in infants aged three to 24 months, setting a PDUFA target date of February 23, 2027. The sNDA is supported b", "url": "https://thedermdigest.com/us-fda-sets-pdufa-for-roflumilast-cream-0-05-in-infants-with-ad/", "source_name": "The Dermatology Digest", "published_at": "2026-07-08T20:09:30", "published_display": "08 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-says-fda-accepted-125906712.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:59:06+00:00", "published_display": "08 Jul 2026 12:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants", "summary": "Arcutis has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.005% for the treatment of mild-to-moderate atopic dermatitis in infants aged 3 months to less than 6 years. The FDA has set a Prescription Drug User Fee A", "url": "https://www.moomoo.com/news/post/72652160/arcutis-fda-to-review-zoryve-for-atopic-dermatitis-in-infants?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T13:09:31", "published_display": "08 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Arcutis application for infant eczema treatment", "summary": "The FDA has accepted Arcutis Biotherapeutics Inc.'s application for ZORYVE cream 0.05% to treat atopic dermatitis in infants aged 3 to 24 months, setting a target action date of February 23, 2027. This follows positive results from a Phase 2 study and comes as Arcutis shares have", "url": "https://www.investing.com/news/company-news/fda-accepts-arcutis-application-for-infant-eczema-treatment-93CH-4781489", "source_name": "Investing.com", "published_at": "2026-07-08T13:09:30", "published_display": "08 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months", "summary": "The FDA has accepted Arcutis' Supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants as young as three months old. This sNDA is supported by positive results from the Phase 3 INTEGUMENT-PED study. If ap", "url": "https://www.moomoo.com/news/post/72651104/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast", "source_name": "Moomoo", "published_at": "2026-07-08T12:10:58", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Supplemental New Drug Application for Arcutis\u2019 ZORYVE\u00ae (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months", "summary": "Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for ZORYVE\u00ae (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA has set a target action date of February 23, 2027. Th", "url": "https://www.manilatimes.net/2026/07/08/tmt-newswire/globenewswire/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-005-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months/2380726/amp", "source_name": "The Manila Times", "published_at": "2026-07-08T12:09:31", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis wins FDA review for ZORYVE in infants as young as 3 months", "summary": "Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA has set a PDUFA target action date of February 23, 202", "url": "https://www.stocktitan.net/news/ARQT/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-dzxv8c9m3k4i.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:09:30", "published_display": "08 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Arcutis Biotherapeutics, Inc. \u2013 NASDAQ:ARQT", "summary": "This article provides the \"Price to sales forward\" financial metric for Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). It appears to be a financial data snippet from TradingView, without further elaborating on the value or implications of this metric. The content focuses on the co", "url": "https://www.tradingview.com/symbols/NASDAQ-ARQT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T18:40:35", "published_display": "05 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Comparative Analysis of Arcutis and Vertex Biotherapeutics", "summary": "This article provides a comparative analysis of Arcutis Biotherapeutics and Vertex Pharmaceuticals based on their FY 2025 financial performance, market position, and future outlook. Arcutis showed significant revenue growth but faces stiff competition and patent litigation for it", "url": "https://intellectia.ai/news/stock/comparative-analysis-of-arcutis-and-vertex-biotherapeutics", "source_name": "Intellectia AI", "published_at": "2026-07-03T14:41:28", "published_display": "03 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/2e75dc09-2807-3507-941d-d552f859c2c8/arcutis-vs.-vertex%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-07-03T12:57:20+00:00", "published_display": "03 Jul 2026 12:57", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Arcutis Biotherapeutics, Inc. announced the grant of 61,000 restricted stock units (RSUs) to 9 newly hired employees. These grants were made under the company's 2022 Inducement Plan, with a grant date of July 1, 2026, as a material inducement for their employment. The RSUs will v", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377798/amp", "source_name": "The Manila Times", "published_at": "2026-07-02T19:40:30", "published_display": "02 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis lures 9 new hires with 61,000 stock awards", "summary": "Arcutis Biotherapeutics (Nasdaq: ARQT) has granted an aggregate of 61,000 restricted stock units (RSUs) to nine new employees under its 2022 Inducement Plan. These awards, approved by the Board\u2019s Compensation Committee, were granted on July 1, 2026, and will vest 25% annually ove", "url": "https://www.stocktitan.net/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-vjhqlzgvqj91.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:39:12", "published_display": "02 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36", "summary": "Needham has reiterated its Buy rating for Arcutis Biotherapeutics (ARQT.US) and maintained its price target of $36. This indicates continued confidence in the company's stock performance and future prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/72276591/needham-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-01T21:39:13", "published_display": "01 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis launches virtual dermatology platform for skin conditions", "summary": "Arcutis Biotherapeutics has launched a virtual health platform to connect patients with board-certified dermatologists for chronic inflammatory skin conditions like eczema and psoriasis. This initiative aims to expand access to care, complementing traditional in-office visits, an", "url": "https://www.investing.com/news/company-news/arcutis-launches-virtual-dermatology-platform-for-skin-conditions-93CH-4768064", "source_name": "Investing.com", "published_at": "2026-07-01T09:11:09", "published_display": "01 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should ZORYVE\u2019s New Pediatric Label and Virtual Platform Expansion Require Action From Arcutis (ARQT) Investors?", "summary": "Arcutis Biotherapeutics received FDA approval to extend ZORYVE cream treatment to children aged 2\u20135 and launched a virtual health platform to connect patients with dermatologists. This expansion supports Arcutis's revenue goals and broadens access to care, but investors should we", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/should-zoryves-new-pediatric-label-and-virtual-platform-expa/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T08:40:50", "published_display": "01 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast", "summary": "Arcutis Biotherapeutics is introducing a new virtual health platform to enhance access to its roflumilast (Zoryve) treatments for chronic inflammatory skin diseases like atopic dermatitis, seborrheic dermatitis, and plaque psoriasis. This platform connects individuals with indepe", "url": "https://thedermdigest.com/arcutis-launches-virtual-dermatology-platform-to-boost-access-to-roflumilast/", "source_name": "The Dermatology Digest", "published_at": "2026-06-30T16:40:11", "published_display": "30 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ARQT) Movement", "summary": "The article provides a real-time analysis of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), highlighting a near-term neutral sentiment amid stronger mid and long-term outlooks. It details institutional trading strategies, including long and short setups with specific entry, target,", "url": "https://news.stocktradersdaily.com/news_release/24/Avoiding_Lag:_Real-Time_Signals_in_ARQT_Movement_063026041402_1782850442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T16:40:11", "published_display": "30 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis launches virtual dermatology platform for skin conditions By Investing.com", "summary": "Arcutis Biotherapeutics has launched a virtual health platform connecting patients with board-certified dermatologists for chronic inflammatory skin diseases like eczema and psoriasis. The platform aims to address barriers to in-person care and expand access to diseases for the c", "url": "https://ca.investing.com/news/stock-market-news/arcutis-launches-virtual-dermatology-platform-for-skin-conditions-93CH-4714064", "source_name": "Investing.com Canada", "published_at": "2026-06-30T13:40:11", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE\u00ae (roflumilast) Indications", "summary": "Arcutis Biotherapeutics has launched a new virtual health platform to improve access to care for individuals with chronic inflammatory skin diseases, including those eligible for ZORYVE. The platform connects patients with independent, board-certified dermatologists through a str", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-individuals-living-with-chronic-inflammatory-skin-diseases-including-approved-zoryve-roflumilast-indications/2375921/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T13:40:11", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-wins-fda-approval-083519488.html", "source_name": "MT Newswires", "published_at": "2026-06-30T08:35:19+00:00", "published_display": "30 Jun 2026 08:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis\u2019 new virtual dermatology platform targets care gaps for 45M Americans", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOUUd6dWM2SHI0cHZNMFV4TDRqNWZCWm96RWpMeENBYkxRTU9MQU82NlJCTjBKdXRpd0NFc1l5NHhnWndrcnpIQU5zN1h6U053c2cxaDliMVB4QXVuV2tCaWdhd0l4bm9KTGlsSXFHV3hDUTBkNzBXMG9DVTZkWjNLTTRSUzBSTmxMY0hOanlmN0R2UHVoMW9Cb25ta3phclRIaGR3eWFUbzVISktvVFljQ2RCMzgwcGVmOWcxeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2", "summary": "Arcutis Biotherapeutics announced FDA approval for ZORYVE cream 0.3% to treat plaque psoriasis in children as young as two, marking it as the first once-daily, non-steroidal topical treatment for this age group. This approval addresses a significant treatment gap, offering a safe", "url": "https://www.quiverquant.com/news/Arcutis+Biotherapeutics+Announces+FDA+Approval+of+Expanded+ZORYVE+Cream+0.3%25+Indication+for+Children+With+Plaque+Psoriasis+Down+to+Age+2", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T22:10:05", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQYjcySGlSREM4OUd5ZmU0WU5BWnRQanF6UmN4NUJBaVg3eUJrTWhBcG5lMHgxNUx0ZGZpRjlpRXpVZTBvSjdpeHlBRDdKYk4xMW9mQ0hvQkRRc1BzZ05EdUt5ZHNNX0R0TndULWIwUFhrd3g1c2FrSlF2TGd4RmYySGZyV3lBZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T23:38:28+00:00", "published_display": "25 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNQVEwQTFqR1FQMlJSbEZaMzRxZHNUVldzQlFSRmxPOTBNQU41M0pUd1N0akZmUExocDc3ckN4aTdrdlU2ajNDT3ZQYS1TX2N1blUtQzRTUlk3LUNFMTZuNFdEZTZHMmtFdnZCbDFRV3pUc0NjRDFySktlRTNJVlVpa3RGV3RrMk05THJkYWM2UWwyRlZKcUpTeUxxMk10TG1EWUtLd21CbEp1b0c4UXFMS21CdkJCXzQ1QVNjQlJlcm0xN2FrVEZBTjNpNA?oc=5", "source_name": "ChartMill", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS1ZMS3JIX3g3eURvVy1oVmYxX0k2N0o0dmNWbGhZMTRKUU1LOEpUd3ptUE9TT2RtTi1NV1VBLXdyWkxEZXdPRHBSYUJZTGtzMlUtVGVSNmZmZVFWelRFRnZXeGhBMWh6dlg4c2RsMjVYNkU0eW5TWHNaNkg2WW4wRURBb05PcFV5Y0w5eFVYYlowN044eDM4MzhzOTQ3aWVfbVFqSElOOWtJNG1tMWFFN1VEb3lIdGVzZ0R5T0FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Howard Welgus sells 21,240 ARQT shares (NASDAQ: ARQT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZjE3OXZjSk1JOHJCY3RIeHZiYUlZcUR6YVlvdmk4b2JqajJHeVdnckxaOEc3TEw4TUFCeWNPN0hvcy1HajJNOHlVTkU3WWZUVzJKdGt4c0ttV2ZDaVZaSXZpU2pxVTlWR3V2SklNUTVBdUtBTzBXVVpNYy1RVV9KYVBxSHpueDlwOU1NdnFpQ2RMQ0ctTFNwVEpYUDhWMmVKS1RNU2VJaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis (ARQT) director Sue-Jean Lin executes planned share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOdmRTU0VVclVuaVFsVGpHWUUwdUxYcmVrS3o3eDAzd2RsLWJRWG0tOFVCUzhoNU1MOVY5LXI1dlJEX2dPQzg3YkxzOVplRnp2YjBQbElYdlVrdjlSVnIyN0ZTczNUODJ1RWFBYmRXY095Yk5RcXFONThoeDV5Qm5xM2R2RlRpRnM2Y3QtakRCQ0haakRYVXBWRklyUlFkaWItOHFSWHE5N2Vyb1AtQ0lCRlBzYmY2SWlERldEY3Vn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Genital Psoriasis Clinical Guidance Publication", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics ARQT Tighter Trailing Losses Test Bullish Profitability Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxNNjdMc2JtLWpfVXdqQzF0ZkllRkZNaDJUczFVYlhLT1RVcXpDZDNmYjZFd0JFRUpyTFJPbktpQTlyVHdJOXpWLXFtUG8tMjY2ZkR1R0xLYjBMLWhqYjBfdFBsTDZVVHVQVl9mQ1BmcUpGRUlFSXhFanctb014OEZrRjlCVkZsY0xoOTZNbEpndy1LNkVvaW1qSl9DZ0RaTWtxVUhmVklwaVBvMy1WWEtPSmlvNnA3Y1JVNjl0dkN0M01oWjRHMXNHOUE3VFNSMkpiUmkyV3VSNG83TFpQUzF4djR0MWtWM0Z3dnoyN2dR0gHzAUFVX3lxTFB5aENocEx1MEJCaVk4eVNoMjV5UDVYM0FtRVAtYmZaeGkxM0RTb2NKdk9DSDRXWHBtbHhVNk1UZjFWcEVHSm5zNVQyT3RWcjF0b1I2RGNoZXRWUDRJZjhXYnBQZ3ZOQ2JsU2d1WDZ3WUJ0ZFpHRXpkZ2Q4aldKQU80M3hTLTBkRTVYbTdEeV9zX0NLTEE2V2JGRzJOaEhGeFhONjcyRFNvdHVneGhBb3JQOENOc184aXpmRDRRbm9UeEJkelZuUkQ0eGh6TFRXa3RQdGFBMjdHYWFIckRZSGdEeERZb2ktamo2YWJOWV9TblRWNA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOdV9DcTFEZmk2YlVSOGwwUDM5d0NERlBoeFJZNXBCT29xQjlTLWRCbTczNjg3alp4RzdkX3RHVWx4UXdzaTRwN3RtVUdNRHFnTUk0LUJCMHl3RVZDbU5rUXVkTG9ZUHd0MXdCdS1JbDUtMkd6LVFDUWM3NmU3Q2hFRHh0NGhONjVOR1hwYURCRC12UDFw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNNmhoZHhENlNpdlE2S0lTeVFoNXYzVzQ4a1k5RGhoUmFxNUdJMTFnUmxPVGVMakw2azNEWXJsOHozcC10SjY3bVNJb3pFeDc0SWFJb1U4eFAyNE5sbjBFeG9RS3ItUmhlRHd3SXY1bnRzUUc4SHNhTHNld3ZhYnF4eVpzbkI0MzR3NWNJS3QxRE96S0dTQkx3MXZDMGMzTTBuVUZhRTA0cUVtQ3FUZ0E?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQekVpbFlvWnhxV2pyX25lRmNseDZXZXNMVHNEUUFYcmlfM1duclJVa0Q4UXhMa0tzand2MlR0VUNkZGljbE1QcUFPUXFud1RJNEdHWW5EMGVvQWlEa0VybnNVeDVSaTY1LXNqTElMRnhkNEw5cmxiRmotSDZOS2xKV3pkQWd2akhwNUp5M3kyTVFQYTd3dW9aRlVxbkUwVDVTbHZfclBVRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQMW5lS013YjJPVV92bU1nNkFhQVNQMXUyOWVKSkhiLWNuWkplTzVyT0FtcXNhRklJZFpaZG5BSTBJR3BFNjN0U3BLSXdSWXFEQ005ZzZtUUVlRnhBdU1GWFBOOG5STTdQc1ZqWVhMRlQyWlFwNmtxT1lOa1p5U0MwZXcySi0tS2hpWFRFWVlBT1hTR0tOY3gtc3VveEhsazRMdTBPeC1fSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOYUZPQzBnS2RwejRhRFl2a3R3dXNSdkNFd3FKWjF5b1R4bzhENE1ESTNaVkRWWWZFcktKSDVGcnppcV9WTFpsQ1k2NUFvMnlRMnBLdHVxZWVUOWFvVVpDSkRLT2RENVFqejd6RHAwZTFqMnpMazU5bHVJdlE1WTF6bTNiWE9DVTJLS2JlREpVSEgxdzVfczhEUnRmdGZFWVFuT3dSZ3ZFYw?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQV0ZGOTlySG93TzhzQVhPNUxXNFgzRnEwVmZQaTV4Q1JWcnNPME8ycEdpNmpIQkIxdmRCdUpNd1g2ZXZTQ2EzUHBfTkpueGZ0T2M1ZHEtaUJic1p3S3Vnc1R4a01pckMxZVR4MUNaZEw3Y2ZUTWxvRy1UNTBlbnlQeUJlczlBdFJSRENncHVOb1c5Ni1iZ0prV3JhUDE5bzVoQWpYNGJGZlNZekIxbEFKMXZR?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOaGI4bDJYaDVJd2ttX1hubWdQbUNYMFZ6Rk9EeTBIdG83NS1aZXluaTVOVlFxRVE3cmVlTUdHMGhXVGxsS25iaU92VHlZczJyYkdmUG9rSUpLeGFVb253NXhDdWtMTUMxZG5qbXFucEFaX2lNOS1aYVAwaGV1M0xjb1dFRmZEOEg0czRMSG1sTnNSYzdpY25OU05Cck9wcE5RZk12LVZvU05uMUFJWUJndjlRbjIxTENUYzdzT0J1S25SSUVOYlFhQXJzWU5WWXphZ3Bldm02bTlpZEU?oc=5", "source_name": "ChartMill", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNRGJmU3k2cVIxSURPemsyQ053NWM3SHhzUHZLZTlvSU9uQnR5UFdOU0k0RVREMEtRNEVNRFNrQmYwanhvT2FfUnp1OW04SEp0SXZrZUdEZWJNRk8zcVZSMDNWVDN5TnNDSlNHWEFobUdPMlBjUWVVS2s5UDJfLVMzcVVBUFROZXFiZnRqS3E4Z2NDdzlxRXJySXpPclRCNzl5TGhoMldJSzdCSEpMMmc?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUTJOQVdhc19UZEh0MzFWN0RmclZ2ZWNWbXladnZvcmJFMkU3TWQ1cURLUHVCWlJlNzBfQ1RkS0JUSl9hYTU2Mnd4bXF5QjdVTEYwZ0ZxNGhpNkI1ejdGWW5ETUJ5VkU2dlFLa1d3a2pKMDF6TVNfMjFVQ1djNzQzb3NVTEZublBMeWF2SzNCVWVsZ1MzSDFHZjRxb2k?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNQ3dodXJ4TDRycGRRTmJqcExnS1NVcDBJQXJBVDI5d21rc1owMFNUMDFTVnpyZ05LUThhdW93XzB5T1REQVRRekhFV2Nqb1Y4UjB0OERHMEQtMTFBeGUyekU4c29VbWRoNDNvN21hTFZTT0RXbHhqelZFckRoVFRXSXFR?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcutis Biotherapeutics (NASDAQ: ARQT) files shelf for multiple securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUFJzeDBnOElmclU3Vzl0emwtdWIySEZfd2xkaVJwMENFaHpZZXlBTkx2UEROcklHVFJ0c3hKdE84akxVMEJlUkUxbElJWnhUWUNyYVlkVGpCRHBuZ2xZOHRLdDBmZjdaN2h6TnNEVXRNUEI0aUhCSzl5UUZKekd0dXFLajNleVdRQzB6V2pEcnFVdGRJS3p4R1NhNmVkSVJkOVJjM09ySjVMc00?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 64, "sentiment_summary": {"positive": 28, "negative": 3, "neutral": 33, "score": 60, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 9.9, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 28, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 27.74, "latest_week": "2026-07-10", "one_week_move": 7.5, "four_week_move": 13.8, "twelve_week_move": 13.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.972104, "market_dynamics_buy_signal": false, "relative_strength": 3.798512, "fair_value_gap": 96.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.3333, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.5% over one week, +13.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 11}, {"label": "simplywall.st", "count": 5}, {"label": "The Manila Times", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Moomoo", "count": 4}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 9}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.5% over one week, +13.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Arcutis to report Q2 2026 financial results on August 5"}], "updated_at": "2026-07-16T03:02:37.655218+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}